Study of intestinal flora and adverse events at the time of eradication of H. pylori
Not Applicable
- Conditions
- Helicobacter pylori
- Registration Number
- JPRN-UMIN000028726
- Lead Sponsor
- Saga University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 65
Inclusion Criteria
Not provided
Exclusion Criteria
1. Persons who were unable to obtain consent from the person or guardian 2. Person who is responsible for research, and who is in the hospital, judged that the attending physician has problems in participation 3. Those who have already taken H. pylori eradication treatment 4. Exclude from H. pylori eradication therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Analysis of intestinal bacterial flora Regarding intestinal flora, the base sequence (read data) of 16S rRNA gene derived from intestinal bacteria obtained by analysis with NGS is grouped (OTU classification) according to the similarity (96 to 97%) , A relative proportion of the microflora composition of each specimen is calculated by performing phylogenetic identification for each OTU. A comparison is made between the groups on this microflora configuration. As a comparison method, the similarity of each flora is examined by comparing beta-diversity (UniFrac analysis and HeatMap cluster analysis) and alfa-diversity comparison (OTU number, chao 1, PD whole tree, Shannon index). In addition, we compare the ratio of the bacterial group constituting the flora and the average number / median value.
- Secondary Outcome Measures
Name Time Method Compare the presence and absence of side reactions and the extent of side reactions between the groups in the group treated with H. pylori eradication therapist combined with or without biofermin R combination.